ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3178

Heart Dysfunction in Systemic Sclerosis: Involvement of a Novel Fibrogenic Stromal Cell Subset

Mara Stellato1, Michal Rudnik1, Florian Renoux2, Elena Pachera1, Karl Sotlar3, Karin Klingel4, Joerg C. Henes5, Przemyslaw Blyszczuk6, Oliver Distler1 and Gabriela Kania1, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Depertment of Rheumatology, University Hospital Zurich, Schlieren, Switzerland, 3Institute of Pathology, Ludwig Maximilians University, Munich, Germany, 4Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, 5Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, 6Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Fibroblasts, fibrosis, heart disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Cardiac dysfunction is a significant cause of the high mortality in systemic sclerosis (SSc). Heart involvement in SSc patients resembles inflammatory dilated cardiomyopathy (iDCM) with inflammation and fibrosis. Myofibroblasts are the main players in cardiac fibrogenesis, but their origin remains unknown. Here, we aim to determine the role of specific myocardial stromal cell subsets in myocardial remodeling in SSc.

Methods: The Fos-related antigen 2 (Fra2) tg mouse model of SSc/iDCM was studied. Immunohistochemistry (IHC) and immunofluorescence (IF) were performed on endomyocardial biopsies (EMBs) from SSc/iDCM patients (n=10) and on hearts from Fra2 tg mice (n=5). Flow cytometry analysis was used to identify different subsets of myocardial stromal cells that were sorted, cultured and stimulated with TGFβ1. The differentiation potential was assessed by qPCR, IF, stress fiber staining, SIRCOL and contraction assay on sorted cells. Proliferation and apoptosis were assessed by BrdU incorporation and caspase 3/7 detection. The antisense oligonucleotide GapmeR was used to downregulate Fra2

Results: Fra2 tg mice showed increased CD45+leukocyte infiltrates and massive collagen deposition in the heart tissue similarly to the myocardium of SSc/iDCM patients. Moreover, the myocardium of Fra2 tg mice revealed increased expression of pro-fibrotic markers such as αSMA, vimentin, collagen I and fibronectin compared to wild type mice. Among cardiac stromal cells (Ter119–CD45–CD31–Sca1+CD29+) four specific stromal cell subsets were identified: gp38+CD90.2–, gp38+CD90.2+, gp38–CD90.2+ and gp38–CD90.2–. The frequency of gp38+CD90.2– (single positive) cells and gp38+CD90.2+(double positive) cells was significantly higher in Fra2 myocardium compared to control mice (p= 0.009; n=11). Importantly, in the myocardium of Fra2 tg mice, the majority of gp38+ cells co-expressed αSMA, vimentin, collagen and fibronectin, indicating that myocardial gp38+stromal cells might proliferate and/or differentiate towards the myofibroblast phenotype. Myocardial single and double positive stromal cells were cultured in vitro. After TGFβ1 stimulation, both cell subsets up-regulated αSMA mRNA levels. Importantly, gp38+stromal cells from Fra2 tg mice showed the presence of αSMA fibers and stress fibers, as well as a stronger contraction capability even without TGFβ1 stimulation. In addition, apoptosis and proliferation were increased in Fra2 cells compared to wild-type cells. These findings indicate that Fra2 overexpression might trigger the differentiation of these cells. Accordingly, Fra2 silencing resulted in a decreased differentiation capability of gp38+stromal cells: mRNA levels of the pro-fibrotic genes αSMA and collagen I were significantly downregulated (p=0.0075 and p=0.0073; n=5). Moreover, Fra2 downregulation impaired the secretion of collagens and the formation of αSMA fibers

Conclusion: Cardiac gp38+ stromal cells might serve as a cellular source of pathological myofibroblasts playing a pivotal role in TGFβ/Fra2-driven myocardial remodeling in SSc. A better understanding of the mechanisms triggering myocardial dysfunction in SSc might be helpful in developing effective therapies


Disclosure: M. Stellato, None; M. Rudnik, None; F. Renoux, Swisslife, 2; E. Pachera, None; K. Sotlar, None; K. Klingel, None; J. C. Henes, None; P. Blyszczuk, None; O. Distler, Bayer, Sanofi, Ergonex, Boehringer Ingelheim, Actelion, Pfizer, 2,4 D Science, Actelion, Active Biotec, Bayer, BiogenIdec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare foundation, Genentech/Roche, GSK, Inventiva, Lilly, medac, MedImmune, Pharmacyclics, Pfizer, Serodapharm, Sinoxa, 5; G. Kania, Bayer, 2.

To cite this abstract in AMA style:

Stellato M, Rudnik M, Renoux F, Pachera E, Sotlar K, Klingel K, Henes JC, Blyszczuk P, Distler O, Kania G. Heart Dysfunction in Systemic Sclerosis: Involvement of a Novel Fibrogenic Stromal Cell Subset [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/heart-dysfunction-in-systemic-sclerosis-involvement-of-a-novel-fibrogenic-stromal-cell-subset/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/heart-dysfunction-in-systemic-sclerosis-involvement-of-a-novel-fibrogenic-stromal-cell-subset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology